Sammanfattning

There are currently no licensed therapeutic treatment or preventive vaccines against Ebolavirus disease, and the 2013-2016 West African outbreak of Ebolavirus disease spread rapidly and resulted in almost 30,000 cases and more than 11,000 deaths. However, the devastating outbreak has spurred the development of novel Ebolavirus vaccines. Here, we demonstrate that alphavirus-based DNA-launched self-replicating RNA replicon vaccines ( DREP) encoding either the glycoprotein (GP) gene or co-expressing the GP and VP40 genes of Sudan or Zaire Ebolavirus are immunogenic in mice inducing both binding and neutralizing antibodies as well as CD8T cell responses. In addition, antibodies were cross-reactive against another Ebolavirus, although the specificity was higher for the vaccination antigen. DREP vaccines were more immunogenic than recombinant MVA vaccines expressing the same Ebolavirus antigens. However, a DREP prime followed by an MVA boost immunization regimen improved vaccine immunogenicity as compared to DREP and MVA homologous prime-boost immunizations. Moreover, we show that a bivalent approach targeting both Sudan and Zaire Ebolavirus can be employed without significant loss of immunity. This opens for further investigation of a pan-Ebolavirus or even a pan-filovirus vaccine.

Publicerad i

Scientific Reports
2018, Volym: 8, artikelnummer: 12459
Utgivare: NATURE PUBLISHING GROUP

Globala målen

SDG3 Säkerställa hälsosamma liv och främja välbefinnande för alla i alla åldrar


UKÄ forskningsämne

Immunologi inom det medicinska området


Publikationens identifierare

DOI: https://doi.org/10.1038/s41598-018-31003-6

Permanent länk till denna sida (URI)

https://res.slu.se/id/publ/96659